Exocrine pancreatic substitution: facts and controversies.
The effect on intraluminal postprandial concentrations of different pancreatic enzymes and on fat absorption were studied in 35 patients with advanced chronic pancreatitis with pancreatic insufficiency. Different regimes were studied: commercial Pankreatin (III) alone or in combination with Cimetidine, Pancrease, dispensed in microspheres, and commercial Pankreatin III compared to an equivalent uncoated preparation (Pankreatin I). Pankreatin induced significant increase in the intestinal concentration of amylase, lipase, and trypsin. Pretreatment with Cimetidine did not increase the enzyme concentrations further. The amount of enzymes in Pancrease capsules are rather small, no effect on concentrations of enzymes could be detected but treatment with Pancrease decreased significantly the fat excretion in faeces. The uncoated Pankreatin I induced a significantly higher increase in enzyme concentrations in the intestine compared to Pankreatin III but the overall effect tested on faecal fat excretion was identical with the two preparations. The results indicate that the estimation of concentration of enzyme at one level of the small intestine without and with enzyme substitution not necessarily gives information on the therapeutical effect of the enzymes.
Worning
H
H
D000328:Adult; D002908:Chronic Disease; D002927:Cimetidine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D010188:Exocrine Pancreatic Insufficiency / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007408:Intestinal Absorption; D050356:Lipid Metabolism; D008875:Middle Aged; D010184:Pancreatic Extracts / Q000008:administration & dosage*; D010194:Pancreatin / Q000627:therapeutic use*; D010195:Pancreatitis / Q000188:drug therapy* / Q000378:metabolism; D013608:Tablets, Enteric-Coated
D010184:Pancreatic Extracts; D013608:Tablets, Enteric-Coated; D002927:Cimetidine; D010194:Pancreatin